Exact Sciences says data support its colon cancer blood test

MedTech Dive September 16, 2024
Susan Kelly

Exact’s test could compete with Guardant Health’s Shield blood test, which received approval from the Food and Drug Administration in July.

Dive Brief:

• Exact Sciences released data from a study of its blood-based colorectal cancer screening test that showed sensitivities of 88.3% for colorectal cancer and 31.2% for advanced precancerous lesions. Specificity, a measure of how well a test identifies people who do not have cancer, was 90.1% for negative samples confirmed by colonoscopy.
• The results, presented Monday at the European Society for Medical Oncology Congress in Barcelona, move the test “one step closer” to giving patients at average risk another non-invasive screening option for colorectal cancer, Paul Limburg, Exact’s chief medical officer for screening, said in a statement.
...

Today's Sponsors

Today's Sponsor